Richmond Pharmacology has appointed John Hotti as Chief Technology Officer (CTO), strengthening the company’s leadership in technology-enabled clinical research.
Hotti brings over 35 years of global technology leadership across Software as a Service (SaaS), financial services, healthcare and enterprise systems. He has led large-scale digital transformations, stabilised mission-critical platforms and delivered secure, scalable technology in highly regulated environments. His experience spans hands-on engineering through to board-level advisory, including supporting major investment decisions and post-acquisition integrations.
In his role at Richmond, Hotti will lead the development of a progressive technology and data strategy to enhance trial delivery, strengthen cybersecurity and compliance, and enable the responsible adoption of AI across clinical operations. This includes advancing platforms that improve data quality, accelerate study timelines and support more efficient, reliable outcomes for sponsors and patients.
John Hotti commented: “My focus will be on building on the strong foundations already in place, advancing our technology and cybersecurity capabilities, and ensuring the responsible use of emerging technologies such as generative AI to deliver secure, scalable, resilient platforms that enhance operational performance across the business and support the company’s long-term goals.”
Jorg Taubel, CEO, added: “John’s experience in delivering secure, scalable technology in regulated environments will be instrumental as we continue to enhance our data capabilities and adopt AI responsibly, supporting high-quality, efficient clinical trials for our partners.”
With deep expertise in AI strategy, cloud architecture, and regulated systems, Hotti will play a key role in strengthening Richmond’s ability to deliver faster, more data-driven clinical research – supporting the development of innovative therapies for patients.